Should You Buy Arena Pharmaceuticals Inc (ARNA) At $27.23? Wed, 22 Nov 2017 13:09:10 +0000 Arena Pharmaceuticals Inc (NASDAQ:ARNA), a biotechnology company based in United States, saw a significant share price rise of over 20% in the past couple of months on the NasdaqGS. WithRead More...
Arena Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARNA) : November 16, 2017 Thu, 16 Nov 2017 17:28:46 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Arena Pharmaceuticals, Inc. a score of 59. Our analysis is based on comparing Arena Pharmaceuticals, Inc. with the following peers – VIVUS, Inc., Orexigen Therapeutics, Inc., Array BioPharma Inc., Athersys, Inc., Zafgen, Inc., GlaxoSmithKline plc Sponsored ADR and ReShape Lifesciences, Inc. (VVUS-US, OREX-US, ARRY-US, ATHX-US, ZFGN-US, GSK-US ... Read more
(Read more...)
Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : November 15, 2017 Wed, 15 Nov 2017 12:50:19 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Arena Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study Mon, 13 Nov 2017 14:44:02 +0000 Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.
Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis Fri, 10 Nov 2017 16:31:00 +0000 SAN DIEGO, Nov. 10, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), today announced that it has completed full enrollment in the etrasimod Phase 2 study in ulcerative colitis (UC). Etrasimod is an investigational-stage, oral, next-generation, sphingosine-1-phosphate (S1P) receptor modulator with improved pharmacology and pharmacokinetics intended for the treatment of autoimmune diseases.
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat Wed, 08 Nov 2017 14:53:02 +0000 Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.
Arena Pharmaceuticals reports 3Q loss Tue, 07 Nov 2017 21:51:46 +0000 On a per-share basis, the San Diego-based company said it had a loss of 86 cents. Losses, adjusted for non-recurring costs, came to 65 cents per share. The results topped Wall Street expectations. The ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.